You are here

Healthcare Economics

 

Valeant Pharmaceuticals announced on May 16 that it would reduce the price of two heart drugs by as much as 40 percent. The program will decrease the price of Nitropress and Isuprel, two of Valeant’s medications. 

 

 

Recent Headlines

Valeant promises to reduce the prices of two heart drugs

Valeant Pharmaceuticals announced on May 16 that it would reduce the price of two heart drugs by as much as 40 percent. The program will decrease the price of Nitropress and Isuprel, two of Valeant’s medications. 

Endologix posts a net loss for first quarter but revenue increases

For the first quarter of 2016, Endologix, Inc.’s revenue increased 16 percent to $42.4 million compared with the same period last year. The company also reported a net loss of $47.7 million for the quarter and a negative adjusted EBITDA of $14.1 million.

Edwards Lifesciences to hold annual shareholder meeting

Edwards Lifesciences will host its annual meeting for shareholders on May 12.

Chiesi agrees to acquire cardiovascular medications from The Medicines Company

Chiesi USA, Inc. agreed to acquire three cardiovascular medications from The Medicines Company on May 9 for up to $792 million. The Medicines Company plans on selling clevidipine (Cleviprex), cangrelor (Kengreal) and its rights to argatroban.

Medtronic hires Parkhill as CFO

Medtronic hired Karen L. Parkhill as the company’s chief financial officer (CFO) on May 4. She will also serve on Medtronic’s executive committee and report to CEO Omar Ishrak.

Impella growth helps Abiomed post strong yearly, quarterly results

Led by strong sales of its Impella devices, Abiomed reported on May 3 that its revenue increased 43 percent to $329.5 million during fiscal year 2016 compared with fiscal year 2015. For the fourth quarter, revenue increased 39 percent to $94.0 million, the 26th consecutive quarter that Abiomed’s revenue has increased by at least 10 percent year-over-year.

Abbott agrees to acquire St. Jude Medical in $25 billion deal

Abbott Laboratories is set to acquire St. Jude Medical in a cash and stock transaction valued at approximately $25 billion.

Boston Scientific’s revenue, profit increases in first quarter

During the first quarter of 2016, Boston Scientific reported sales of $1.964 billion, a 13 percent increase from the same period last year. The company had adjusted earnings per share of $0.28 per share, up from $0.21 per share a year ago. Boston Scientific also raised its revenue and earnings guidance for the full year.

St. Jude Medical’s revenue, earnings increase in first quarter

For the first quarter of fiscal year 2016, St. Jude Medical’s net sales increased 8 percent to $1.448 billion and its adjusted earnings increased 9 percent to $0.90 per share from the first quarter of last year.

Medtronic provides update on tender offer

Medtronic announced it had tendered approximately $5.8 billion in aggregate principal of outstanding debt securities as of 5:00 p.m. Eastern time on April 13, the early deadline for a previously announced tender offer.

Pages